Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial
Isabel Leroux-Roels,Cathy Maes,Francesca Mancini,Bart Jacobs,Eleanna Sarakinou,Azhar Alhatemi,Jasper Joye,Silvia Grappi,Giulia Luna Cilio,Alimamy Serry-Bangura,Claudia G Vitali,Pietro Ferruzzi,Elisa Marchetti,Francesca Necchi,Rino Rappuoli,Iris De Ryck,Jochen Auerbach,Anna M Colucci,Omar Rossi,Valentino Conti,Francesco Berlanda Scorza,Ashwani Kumar Arora,Francesca Micoli,Audino Podda,Usman N Nakakana,Francesco Citiulo,Emilia Cappelletti,Gianmarco Gasperini,Carlo Giannelli,Alessandra Acquaviva,Luigi Sollai,Renzo Alfini,Maria Grazia Aruta,Laura Bartle Martin,Shigella project team
DOI: https://doi.org/10.1093/infdis/jiae273
2024-06-12
The Journal of Infectious Diseases
Abstract:Background We report data from Stage 1 of an ongoing two-staged, phase I/II randomized clinical trial (NCT05073003) with a 4-component Generalized Modules for Membrane Antigens-based vaccine against Shigella sonnei and S. flexneri 1b, 2a and 3a (altSonflex1-2-3, GSK). Methods 18–50-year-old Europeans (N=102) were randomized (2:1) to receive two injections of altSonflex1-2-3 or placebo at 3- or 6-month interval. Safety and immunogenicity were assessed at pre-specified timepoints. Results The most common solicited administration-site event (until 7 days post-each injection) and unsolicited adverse event (until 28 days post-each injection) were pain (altSonflex1-2-3: 97.1%; Placebo: 58.8%) and headache (32.4%; 23.5%), respectively. All serotype-specific functional IgG antibodies peaked 14–28 days post-injection 1 and remained substantially higher than pre-vaccination at 3 or 6 months post-vaccination; the second injection did not boost but restored the initial immune response. The highest seroresponse rates (≥4-fold increase in titers over baseline) were obtained against S. flexneri 2a (ELISA: post-injection 1: 91.0%; post-injection 2 [Day {D}113; D197]: 100%; 97.0%; serum bactericidal activity (SBA): post-injection 1: 94.4%; post-injection 2: 85.7%; 88.9%) followed by S. sonnei (ELISA: post-injection 1: 77.6%; post-injection 2: 84.6%; 78.8%; SBA: post-injection 1: 83.3%; post-injection 2: 71.4%; 88.9%). Immune responses against S. flexneri 1b and S. flexneri 3a, as measured by both ELISA and SBA, were numerically lower compared to those against S. sonnei and S. flexneri 2a. Conclusions No safety signals or concerns were identified. altSonflex1-2-3 induced functional serotype-specific immune responses, allowing further clinical development in the target population.
immunology,infectious diseases,microbiology